Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 25;13(2):87.
doi: 10.3390/toxins13020087.

Use of Botulinum Neurotoxin in Parkinson's Disease: A Critical Appraisal

Wolfgang H Jost  1
Affiliations
Review

Use of Botulinum Neurotoxin in Parkinson's Disease: A Critical Appraisal

Wolfgang H Jost. Toxins (Basel). .

Abstract

For well over 30 years, the botulinum neurotoxin (BoNT) has been used for a large number of indications, some of which however have not been licensed. Admittedly, approval varies in many countries and this permits a large spectrum for evaluation. Thus, BoNT is used for patients with Parkinson's disease (PD) and other Parkinson's syndromes (PS) in varying degrees of frequency. We have to distinguish between (1) indications that are either approved or (2) those not approved, (3) indications that might be a result of PS and (4) finally those which appear independent of PS. The most important indication for BoNT in PS patients is probably sialorrhea, for which approval has been granted in the majority of countries. Cervical dystonia is a frequent symptom in PS, with anterocollis as a specific entity. A further indication is blepharospasm in the different forms, especially the inhibition of eyelid opening in atypical PS. The use of BoNT in cases of camptocormia, the Pisa syndrome and neck rigidity is still a matter of debate. In dystonia of the extremities BoNT can be recommended, especially in dystonia of the feet. One well-known indication, for which however sufficient data are still lacking, involves treating tremor with BoNT. As to autonomic symptoms: Focal hyperhidrosis and detrusor hyperactivity can be mentioned, in this last case BoNT has already been approved. A number of further but rare indications such as freezing-of-gait, dyskinesia, and dysphagia will be discussed and evaluated.

Keywords: Parkinson’s disease; Pisa syndrome; blepharospasm; botulinum neurotoxin; camptocormia; dyskinesia; focal dystonia; non-motor symptoms; sialorrhea; torticollis; tremor.

PubMed Disclaimer

Conflict of interest statement

W.H.J. is speaker and advisor for: Abbvie/Allergan, Bial, Desitin, Ipsen, Merz, UCB, and Zambon.

Figures

Figure 1
Figure 1
Tarsal injection of the orbicularis oculi muscle [14].
Figure 2
Figure 2
Ultrasound image of the levator scapulae muscle. Clearly visible are the four parts of the muscle and the change in morphology compared to the norm (notably rounded).
Figure 3
Figure 3
(a) Injection into the parotid gland; (b) sonography of submandibular gland.
Figure 4
Figure 4
Sonography of the calf with the long toe flexor (M. flexor digitorum longus).
See this image and copyright information in PMC

References

    1. Hallett M., Albanese A., Dressler D., Segal K.R., Simpson D.M., Truong D., Jankovic J. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013;67:94–114. doi: 10.1016/j.toxicon.2012.12.004. - DOI - PubMed
    1. Simpson D.M., Hallett M., Ashman E.J., Comella C.L., Green M.W., Gronseth G.S., Armstrong M.J., Gloss D., Potrebic S., Jankovic J., et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86:1818–1826. doi: 10.1212/WNL.0000000000002560. - DOI - PMC - PubMed
    1. Jankovic J. Disease-oriented approach to botulinum toxin use. Toxicon. 2009;54:614–623. doi: 10.1016/j.toxicon.2008.11.013. - DOI - PubMed
    1. Jocson A., Lew M. Use of botulinum toxin in Parkinson’s disease. Parkinsonism Relat. Disord. 2019;59:57–64. doi: 10.1016/j.parkreldis.2018.12.002. - DOI - PubMed
    1. Jost W.H. Zulassungen der Botulinumtoxin-A-Präparate. Psychopharmakotherapie. 2018;25:240–242.

MeSH terms

Substances